Ralf Otto Named COO at Rentschler Biopharma
Biopharm industry veteran Ralf Otto named to lead development and manufacturing at Rentschler Biopharma.
Rentschler Biopharma, a contract development and manufacturing organization for biopharmaceuticals, appointed Ralf Otto as chief operating officer (COO), effective Feb. 1, 2018, succeeding Thomas Siklosi, who will move to Dr. Rentschler Holding GmbH & Co. KG, according to a Jan. 31, 2018 press statement.
Otto-who will be responsible for development, manufacturing, and quality management-has more than 20 years at senior positions in industry and management consulting and has overseen all stages of the biopharmaceutical value chain.
Most recently, he was a Partner at McKinsey & Company. Previously, he held executive positions in cell biology and biopharmaceutical manufacturing at Boehringer Ingelheim and as vice-president Biopharma Operations, Otto headed the Boehringer site in Fremont, CA.
Source: Rentschler Biopharma SE
Benuvia Granted GMP Certification by Brazil National Health Surveillance Agency
March 14th 2025The certification allows Benuvia to produce pharmaceutical products for companies, either local to Brazil or international, that may be looking for compliant and high-quality production capabilities in the Brazilian pharmaceutical market.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
